To develop a 99m Tc renal tracer with a capacity to measure effective renal plasma flow comparable to that of the clinical gold standard 131 I-o-iodohippurate ( 131 I-OIH) and superior to that of 99m TcOmercaptoacetyltriglycine ( 99m TcO-MAG3), which has a clearance only 50-60% that of 131 I-OIH, we investigated 99m Tc tricarbonyl nitrilotriacetic acid (Na 2 [ 99m Tc(CO) 3 (NTA)]). This radiopharmaceutical, which is based on an aminopolycarboxylate ligand, is formed as a single species and has a dangling carboxylate group favoring tubular transport.
INTRODUCTION
Our goal has been the development of a 99m Tc renal tracer with a capacity to measure effective renal plasma flow (ERPF) comparable to that of the gold standard, p-aminohippurate. 131 I-oiodohippurate ( 131 I-OIH) has similar biological properties to p-aminohippurate and has been used as an imaging agent and as a tracer to measure ERPF. However, 131 I-OIH has suboptimal imaging characteristics because of its 363-keV photon, delivers relatively high radiation doses to kidney and thyroid in patients with impaired renal function as a result of the beta emission of 131 I (1), and it is no longer clinically available in the United States.
To accomplish our goal, we initially explored renal agents with the [ 99m Tc(V)O] 3+ core, such as 99m TcO-mercaptoacetyltriglycine ( 99m TcO-MAG3) (2) (3) (4) (5) , 99m TcO-ethylenedicysteine ( 99m TcO-EC) (6) and 99m TcO-mercaptoacetamide-ethylenecysteine ( 99m TcO-MAEC) (7, 8) . All of those agents gave excellent scintigraphic images, but their plasma clearances were still significantly less than that of 131 I-OIH. In a continuing effort to develop renal imaging agents with higher clearances, we shifted our focus to the fac-[ 99m Tc(I)(CO) 3 ] + core: This core provides a straightforward reaction with a multitude of ligands with a variety of ligating groups (9) ; the small size of this core relative to 99m TcO complexes such as 99m TcO-MAG3 might facilitate more efficient tubular transport; the high chemical and kinetic stability resulting from the 99m Tc-tricarbonyl core provides ideal parameters for the efficient labeling of lowmolecular-weight biomolecules, an IsoLink kit (Covidien) is available for the convenient preparation of the water-and air-stable [ 99m Tc(I)(CO) 3 (H 2 O) 3 ] + precursor (10, 11) ; and the first renal radiopharmaceutical with a 99m Tc-tricarbonyl core evaluated in humans, Na[ 99m Tc (CO) 3 lanthionine], proved to be an excellent renal imaging agent (12), although its plasma clearance and the rate of renal excretion were still lower than those of 131 I-OIH.
We chose the aminopolycarboxylate ligand nitrilotriacetic acid (NTA) for further investigation because it has a suitable chelating moiety, with the amine and carboxyl donor groups allowing tridentate coordination to the 99m Tc(CO) 3 core to form a stable, single product with a dangling carboxyl group that is highly hydrophilic, favoring tubular transport rather than hepatobiliary excretion. Finally, we expected that Na 2 [ 99m Tc(CO) 3 (NTA)] would be dianionic at physiological pH, with one negative charge associated with the metal inner coordination sphere and the second negative charge associated with the dangling CO 2 − : This charge distribution is shared by 99m TcO-MAG3 and is associated with a rapid plasma clearance, efficient tubular extraction, and a rapid rate of renal excretion. (14) . Tissue and organ radioactivity was measured with a gamma counter (Packard Cobra II γ-Counter; Perkin Elmer).
MATERIALS AND METHODS

General
Synthesis of Na 2 [Re(CO) 3 (NTA)]
The Na 2 [Re(CO) 3 (NTA)] complex was synthesized as a nonradioactive reference compound. A solution of NTA (0.082 g, 0.3 mmol in 3 mL of water) was added to a 0.1 M aqueous solution of [Re(CO) 3 (H 2 O) 3 ]OTf (3 mL); the pH was adjusted to 7 with 1 M sodium hydroxide, and the reaction mixture was stirred at room temperature for 2 h. The volume of the reaction mixture was reduced to 2 mL by rotary evaporation, and this solution was passed through a column (Sephadex G-15; Aldrich) eluted with deionized water. The product fractions were collected, the solvent was removed under vacuum, and the white residue was dried to yield Na 2 [Re (CO) 3 
Radiosynthesis of Na 2 [ 99m Tc(CO) 3 (NTA)] and 131 I-OIH
The NTA ligand was labeled as previously described (15) . Briefly, 0.5 mL of a freshly prepared solution of the [ 99m Tc(CO) 3 (H 2 O) 3 ] + precursor (pH ~ 7-8) was added to a vial containing 1.0 mg of the NTA ligand in 0.2 mL of water. The pH of the solution was adjusted to ~ 7 with 1 M sodium hydroxide, heated at 70 °C for 15 min and cooled to room temperature. Na 2 [ 99m Tc (CO) 3 (NTA)] was separated from unlabeled ligand by HPLC; the radiochemical purity was greater thatn 99%. Methanol was partially removed by nitrogen gas, and the aqueous solution of Na 2 [ 99m Tc(CO) 3 (NTA)] was buffered in a physiological phosphate buffer at pH 7.4. 131 I-OIH was prepared by the isotope exchange reaction between non-radioactive hippuran (OIH) and radioactive sodium iodide (Na 131 I) according to the method reported by Anghileri (16) and modified as follows for simplicity and to improve yield and purity. Cold OIH (10-20 mg) and ammonium sulfate (5-10 mg) were placed in a sterile vial, which was closed with a rubber stopper and sealed with aluminum. Na 131 I (1 mL of a 185-370 MBq/mL solution) was transferred to the vial, and a syringe filled with activated carbon was connected to the vial via a needle placed through the rubber stopper. The solution was heated at 140 °C for 30 min. During the heating, all the solvent evaporated, leaving solid residue at the bottom of the vial. Sterile water (1 mL) was added to the dry residue, and the process was repeated. After the residue had been cooled to room temperature, the solid was dissolved in 5 mL of saline. The solution was then transferred to a vial containing microporous carbon chips, which had been impregnated with freshly precipitated silver chloride (17) , and the vial was shaken for 10 min. Next, the solution was passed through a sterile 0.22 μm filter unit (Millex-GS; Millipore) into a sterile, pyrogen-free empty vial to ensure sterility. The final concentration was approximately 111-296 MBq/5 mL. The radiochemical purity of 131 I-OIH was determined by thin-layer chromatography (TLC) using silica gel plates (60F-254; Merck) as the solid phase and ethanol:ethyl acetate:ammonium hydroxide (20:20:1) as a mobile phase. In this system, the 131 I-OIH had a retention factor of 0.3, and radioiodide had a retention factormof 0.9. 131 I-OIH was obtained with a 98-99% labeling yield.
In Vitro Stability
The buffered solution of Na 2 [ 99m Tc(CO) 3 (NTA)] was evaluated by HPLC at 24 h to assess stability. In addition, HPLC-purified samples of Na 2 [ 99m Tc(CO) 3 (NTA)] (0.1 mL) were mixed with 0.1 M solutions of histidine and cysteine (0.9 mL) and incubated at 37 °C; aliquots were analyzed by HPLC at 1, 2 and 4 h to evaluate decomposition.
Biodistribution Studies
All animal experiments followed the principles of laboratory animal care and were approved by the Institutional Animal Care and Use Committee of Emory University. Na 2 [ 99m Tc (CO) 3 (NTA)] was evaluated in 2 experimental groups of Sprague Dawley rats. Rats in both groups were anesthetized with ketamine and xylazine (2 mg/kg of body weight) injected intramuscularly, with additional supplemental anesthetic as needed. In the first group of 10 normal rats (group A), the bladder was catheterized by use of heat-flared polyethylene (PE-50) tubing (Becton, Dickinson and Co). In the second group of 6 rats (group B), the abdomen was open by a midline incision and both renal pedicles were ligated to produce a model of renal failure; thus no urine was collected.
A solution containing Na 2 [ 99m Tc(CO) 3 (NTA)] (3.7 MBq/mL [100 μCi/mL]) and 131 I-OIH (925 kBq/mL [25 μCi/mL]) was prepared (pH ~ 7.4) and 0.2-mL doses were injected intravenously via a tail vein. One additional aliquot (0.2 mL) for each time point was diluted to 100 mL, and three 1-mL portions of the resulting solution were used as standards.
In group A, 5 animals were sacrificed at 10 min, and 5 at 60 min, after injection. A blood sample was obtained, and the kidneys, heart, lungs, spleen, whole stomach and sections of the duodenum and ascending colon were removed and placed in counting vials. The whole liver was weighed, and random sections were obtained for counting. Samples of blood and urine were also placed in counting vials and weighed. Each sample and the standards were placed in a γ-counter; counts were corrected for background radiation, physical decay, and spillover of 131 I counts into the 99m Tc window. The percentage of the dose in each tissue or organ was calculated by dividing the counts in each tissue or organ by the total injected counts. The percentage injected dose (%ID) reported for the bowel was based on the combined counts of the duodenum and colon samples. The %ID in whole blood was estimated by assuming a blood volume of 6.5% of total body weight.
The 6 group B rats were sacrificed 60 min after injection. Selected organs, blood, and all of the small and large intestines were collected and counted as described above. The %ID reported for the bowel was based on the combined counts in the small and large intestines.
Renal Clearance, Extraction Fraction, Plasma Protein Binding (PPB) and Erythrocyte Uptake
Two male rats were anesthetized as described above and placed on a heated surgical table. Following tracheostomy, the left jugular vein was cannulated with 2 pieces of PE-50 tubing (1 for infusion of radiopharmaceuticals and 1 to infuse normal saline [5.8 mL/h] to maintain hydration and additional anesthetic [5 mg/h] as necessary). The right carotid artery was cannulated for blood sampling, and the bladder was catheterized with PE-50 tubing. The core temperature of each animal was continually monitored throughout the study using a rectal temperature probe. Na 2 [ 99m Tc(CO) 3 (NTA)] (3.7 MBq/mL [100 μCi/mL]) and 131 I-OIH (1.85 MBq/mL [50 μCi/mL]) were coinfused at a flow rate of 1.7 ml/h for 60 min to establish steadystate blood levels. Urine was then collected for three 10-min clearance periods, and midpoint blood samples (0.5 mL) were obtained. The blood samples were centrifuged for 15 min and plasma samples were obtained. Plasma clearance (mL/min) was determined as UV/P, where U is the urine radioactivity concentration, V is the urine volume excreted per minute, and P is the plasma radioactivity concentration. The average of the three 10-min clearance measurements was used as the clearance value.
The extraction fraction was measured at the conclusion of the clearance measurements by obtaining a left renal venous blood sample (0.5 mL), followed immediately by a carotid artery sample (3 mL) . Both blood samples were centrifuged immediately after collection to obtain plasma samples. Extraction fraction was calculated by measuring the difference between the arterial and venous plasma sample: (arterial concentration − venous concentration)/arterial concentration.
PPB was determined by ultrafiltration (Centrifree micropartition system; Amican Inc.) of 1 mL of plasma obtained from the carotid artery sample: (1 −[ultrafiltrate concentration/plasma concentration]) × 100. Arterial blood samples were placed in capillary tubes and centrifuged to determine the hematocrit. Samples of the whole blood and packed cells (~ 0.3 mL each) were pipetted into counting tubes, weighed, and counted. The percent uptake in the erythrocytes was calculated from the whole blood (counts/g) and packed cells (counts/g). Percentage erythrocyte uptake was calculated as (counts/g in erythrocytes × hematocrit)/(counts/g in whole blood). No correction was made for plasma trapped in the red blood cells sample. PPB and erythrocyte uptake were calculated in duplicate and the mean values reported.
In Vivo Stability
To assess in vivo stability, 4 rats were anesthetized and injected with Na 2 [ 99m Tc(CO) 3 (NTA)] (18.5 Mbq [0.5 mCi]) via a tail vein. Two rats were prepared for a 10-min urine collection as described above, and arterial blood was collected by cardiac puncture from the remaining 2 rats at 2-3 min after injection. Urine and plasma samples were analyzed by HPLC to determine if the complex was metabolized in the plasma or by the kidney.
Statistical Analysis
All results are expressed as the mean ± SD. To determine the statistical significance of differences between the 2 groups, comparisons were made with the 2-tailed Student t test for paired data; a P value of less than 0.05 was considered to be statistically significant.
RESULTS
Chemistry and Radiochemistry
The synthesis of the [Re(CO) 3 (NTA)] 2− complex has been previously reported (18) , However, that method used (NEt 4 ) 2 [Re(CO) 3 Br 3 ] as a rhenium-tricarbonyl precursor and required heating at 80 °C for 2.5 h to form the Na/NEt 4 [Re(CO) 3 (NTA)] complex in good yield but as a mixture of Na/NEt 4 salts. To avoid byproducts containing the [NEt 4 ] + counterion and to obviate an extensive purification process, we started with our [Re(CO) 3 (H 2 O) 3 ]OTf precursor and were able to obtain the Na 2 [Re(CO) 3 (NTA)] complex exclusively as a Na + salt, as confirmed by MS, in 89% yield after only 2 h of stirring at room temperature. The only signals present in the 1 H NMR spectrum were those from the coordinated NTA ligand and were consistent with data reported in the literature (18) .
The NTA ligand was successfully labeled with the 99m Tc-tricarbonyl precursor (Fig. 1) , and Na 2 [ 99m Tc (CO) 3 (NTA)] was isolated with the high radiochemical purity of more than 99%. Because technetium and rhenium complexes with identical ligands have essentially identical coordination parameters, we confirmed the identity of Na 2 [ 99m Tc (CO) 3 (NTA)] by coinjecting it with Na 2 [Re(CO) 3 (NTA)] and comparing their HPLC profiles. The rhenium and 99m Tctricarbonyl complexes had the same retention time (17 min).
In Vitro and in Vivo Stability
The stability of Na 2 [ 99m Tc(CO) 3 (NTA)] was examined in vitro in a physiological phosphate buffer at pH 7.4. HPLC analysis of an aliquot of the incubated sample revealed only intact 99m Tc complex for 24 h. When challenged with an excess of cysteine and histidine at 37 °C for 4 h, Na 2 [ 99m Tc (CO) 3 (NTA)] was, completely inert and showed no sign of transchelation or decomposition.
We evaluated the stability of Na 2 [ 99m Tc(CO) 3 (NTA)] in vivo by comparing the HPLC chromatograms of the injected 99m Tc complex with the 99m Tc complex recovered in the urine collected during the first 10 min after injection and in the plasma sample obtained 2-3 min after injection. As shown in Figure 2 , there was only one peak in urine (Fig. 2B) and plasma (Fig. 2C) , and each had an elution time identical to that of the injected complex ( Fig. 2A) , indicating in vivo stability.
Biodistribution Studies
The biodistribution of Na 2 [ 99m Tc(CO) 3 (NTA)] in normal rats (group A) and in rats with simulated renal failure (group B) is shown in Table 1 and Figure 3 . In the normal group A rats, the blood clearance of Na 2 [ 99m Tc(CO) 3 (NTA)] was rapid and comparable to 131 I-OIH, with only 4.2 ± 0.9% of the injected dose remaining in the blood 10 min and 0.4 ± 0.2% at 60 min after injection ( Table 1 ). The activity of Na 2 [ 99m Tc(CO) 3 (NTA)] in urine as a percentage of 131 I-OIH was 108 ± 9% at 10 min and 101 ± 5% at 60 min; there was no difference in the %ID in the urine for Na 2 [ 99m Tc(CO) 3 (NTA)] and 131 I-OIH at 10 and 60 min (P = 0.14 and 0.5, respectively). Na 2 [ 99m Tc(CO) 3 (NTA)] demonstrated a high specificity of renal excretion, with less than a mean of 0.8% of the total injected activity present in heart, lungs, spleen, blood and liver at 60 min, compared to 1.1% for 131 I-OIH (P = 0.01).
The group B rats had ligation of both renal pedicles to simulate renal failure. Na 2 [ 99m Tc (CO) 3 (NTA)] was better retained in the blood at 60 min (19.9%) than was 131 I-OIH (15.1%; P < 0.001). Bowel activity was substantially less for Na 2 [ 99m Tc(CO) 3 (NTA)] than for 131 I-OIH (5.6% versus 14.6%, respectively [P < 0.001]), indicating that renal failure results in less hepatobiliary excretion or intestinal secretion of Na 2 [ 99m Tc(CO) 3 (NTA)] than of 131 I-OIH (Table 1 ). The minimal renal activity noted with both tracers was probably secondary to capsular blood flow (Table 1; Fig. 3 ).
The PPB of Na 2 [ 99m Tc(CO) 3 (NTA)] averaged 67 ± 7% and erythrocyte uptake was low (7 ± 2%) compared to 44 ± 10% and 35 ± 1%, respectively, for 131 I-OIH. The plasma clearance of Na 2 [ 99m Tc(CO) 3 (NTA)] was comparable to that of 131 I-OIH (3.08 mL/min/100g vs. 2.96 mL/ min/100g, respectively). The extraction fraction of Na 2 [ 99m Tc(CO) 3 (NTA)] was 93.5 ± 3.8%, versus an extraction fraction of 67.9 ± 6.1% for 131 I-OIH.
DISCUSSION
[ 99m Tc(CO) 3 (NTA)] 2− has been synthesized previously (15, 19) , but we could not find any biodistribution data reported in the literature. 99m Tc complexes of NTA and NTA derivatives have been prepared by stannous reduction of pertechnetate and investigated in rats (20, 21) , and dogs (22) . These results (20) (21) (22) have been disappointing in regard to the rate and specificity for renal excretion, but the stannous reduction-labeling procedure likely produced a mixture of products, including dimers, trimers and tetramers, all with very different rates and specificities for renal excretion. Consequently, the suboptimal renal characteristics of 99m Tc-NTA prepared by stannous reduction might not be applicable to a well-characterized tracer with a tricarbonyl core such as Na 2 [ 99m Tc(CO) 3 
In fact, a number of factors led us to believe that Na 2 [ 99m Tc(CO) 3 (NTA)] would be an excellent renal agent. Na 2 [ 99m Tc(CO) 3 (NTA)] is highly hydrophilic, with a dangling carboxylate group favoring tubular transport rather than hepatobiliary excretion, and it is formed as a single species with a well-established structure based on the analytical characterization of its rhenium analogue. The rhenium(I) center and the anionic part of the [NTA] 2− ligand, the tertiary amine and both carboxylate groups from the coordinated IDA chelating moiety, have a net negative charge. At pH 7.4, the pendant carboxyl group is deprotonated (the pK a of the carboxylic acid is ~ 3); thus, both the rhenium and 99m Tc complexes have a dianionic overall charge at physiological pH similar to Na 2 [ 99m TcO(MAG3)], Na 2 [ 99m TcO(EC)], Na 2 [ 99m TcO(MAEC)], and Na 2 [ 99m Tc(CO) 3 (carboxymethylmercaptosuccinic acid)] (14) . Na 2 [ 99m Tc(CO) 3 (NTA)] proved to be a stable complex, and its pharmacokinetic characteristics in normal rats were superior to those of the other 99m Tc-tricarbonyl renal tubular tracers we previously tested (12, 14, 23) and comparable to those of 131 I-OIH (Table 2 ). In humans, a renal tracer must be highly specific for renal excretion so that its plasma clearance provides an accurate measurement of renal function; consequently, it is particularly important that the tracer not be cleared via the hepatobiliary tract or secreted across the intestinal mucosa in patients with impaired renal function. In our animal model of renal failure, Na 2 [ 99m Tc(CO) 3 (NTA)] was highly promising because it had significantly less intestinal activity than 131 I-OIH. In addition, the renal clearance of Na 2 [ 99m Tc(CO) 3 (NTA)] in rats was comparable to that of 131 I-OIH, which was equivalent to that reported in the literature (3) . Although Na 2 [ 99m Tc (CO) 3 (NTA)] and 131 I-OIH had similar clearances, the extraction fraction of Na 2 [ 99m Tc (CO) 3 (NTA)] appeared to be higher than that of 131 I-OIH (93.5% vs 67.9%). This observation probably reflects an underestimation of the 131 I-OIH extraction fraction due to dissociation or leakage of 131 I-OIH from the red blood cells back into the plasma in the renal vein sample before or during centrifugation. Our results showed that the red cell uptake of 131 I-OIH in rats was 35%, compared to 7% for Na 2 [ 99m Tc(CO) 3 (NTA)]; consequently, leakage of the tracer from the red cells back into the renal vein plasma would be more problematic for 131 I-OIH than for Na 2 [ 99m Tc(CO) 3 (NTA)]. The minimal red cell binding is another potential advantage of Na 2 [ 99m Tc(CO) 3 (NTA)], compared to 131 I-OIH, because under equilibrium conditions 15-20% of the activity is, from 131 I-OIH in human blood bound to or inside of the red cells (4).
The kinetics and metabolism of the NTA ligand itself have been investigated in several species, including humans (24, 25, 26) . NTA has not been found to be teratogenic or genotoxic but has induced urinary tract tumors in rats and mice at extremely high doses (840 mg/kg of body weight per day for 2 y (27)). The oral median lethal dose of Na 3 NTA·H 2 O in rodents is about 2000 mg/kg (28) . Limited information exists regarding the toxicity of NTA in humans. Eight human volunteers did ingest a single dose of NTA (10 mg), and physical examination, blood chemistry analysis, and urinalysis showed no evidence of adverse effects (24) . Because NTA induces tumors only at doses higher than those that are nephrotoxic, NTA is classified in Group IIIB (possibly carcinogenic to man). On the basis of two-year studies in rats to determine the lowest no-observed-adverse-effect level for a nephrotoxic effect, Health Canada has determined the acceptable daily intake in drinking water to be 10 μg/kg per day (25) . In our studies, no free NTA ligand was injected because the ligand was separated from the complex by HPLC prior to injection, and even the administrated dose of the Na 2 [ 99m Tc(CO) 3 (NTA)] complex was extremely small, at less than 0.2 μg/kg, which is lower than the acceptable daily intake of NTA. Consequently, even if all the 99m Tc dissociated from the complex, the remaining NTA would still be a safe level. In a kit formulation, free NTA would be injected, but assuming that it would be on the same order as MAG3 (1 mg/vial) then the dose of NTA injected (μg/kg) would likely still be below the toxicity level established by Health Canada for acceptable daily intake. ).
FIGURE 2.
High-performance liquid chromatograms of [ 99m Tc(CO) 3 (NTA)] 2− before injection (A), in urine at 10 min after injection (B), and in plasma at 2-3 min after injection (C). Biodistribution of [ 99m Tc(CO) 3 (NTA)] 2− and 131 I-OIH in normal rats (n = 5) at 10 min after injection (A) and 60 min after injection (B) and in rats with renal pedicle ligation (n = 6) at 60 min after injection (C), expressed as % ID) per organ, blood and urine. 
